Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma

Next Previous
Trial Profile

A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Diagnostic use; Registrational
  • Sponsors Navidea Biopharmaceuticals

Most Recent Events

  • 16 Oct 2016 According to a Norgine Biopharmaceuticals media release, data from this study were presented at the European Association of Nuclear Medicine (EANM) 2016.
  • 15 Apr 2015 Results of lymph node detection in oral cancer will be presented at the 2015 American Head & Neck Society Annual Meeting & Translational Research Meeting.
  • 25 Mar 2015 According to a Navidea Biopharmaceuticals media release, data from this study were presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top